- Home
- STTK vs GPRK Comparison
STTK vs GPRK Comparison
Compare STTK & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STTK | GPRK |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | Colombia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.4M | 649.0M |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | STTK | GPRK |
|---|---|---|
| Price | $5.65 | $11.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $15.22 | $10.85 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 0.80% |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | $19.28 |
| Revenue Next Year | N/A | $17.77 |
| P/E Ratio | ★ N/A | $12.70 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $5.75 |
| 52 Week High | $8.33 | $13.13 |
Technical Indicators
Market Signals| Indicator | STTK | GPRK |
|---|---|---|
| Relative Strength Index (RSI) | 35.85 | 53.21 |
| Support Level | $3.55 | $8.98 |
| Resistance Level | $7.83 | $11.68 |
| Average True Range (ATR) | 0.46 | 0.39 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 5.65 | 63.24 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About GPRK Geopark Ltd
GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.